Presentation, management patterns and outcome of small cell lung cancer and stage III non-small cell lung cancer in Saudi Arabia: a multicentre retrospective observational study (REVEAL Study)
- Journal of Cancer Prevention & Current Research
-
Abdul Rahman Jazieh,<sup>1</sup> Hatoon M Bakhribah,<sup>2</sup> Hazem Elashry,<sup>3</sup> Nafisa Abdelhafiez<sup>4</sup>
PDF Full Text
Abstract
Background: The advent of
immune checkpoint inhibitors (ICIs) and targeted therapy has resulted in a
significant paradigm shift in the small (SCLC) and non-small cell lung cancer
(NSCLC) management landscape. However, limited real-world evidence is available
regarding the standard of care practice and treatment outcomes of both in the
Kingdom of Saudi Arabia (KSA). Thus, the REVEAL study evaluated the clinical
presentation, treatment patterns, and outcomes of SCLC and stage-III NSCLC in
KSA prior to the availability of ICIs.
Methods: The REVEAL was a multicentre
retrospective study that retrieved data from adult patients diagnosed with
primary SCLC (extensive or limited stage) or stage-III NSCLC between 2015 and
2019. Retrieved records included demographic and clinical characteristics,
treatment regimens, disease response, and survival outcomes.
Results: The cohort comprised 23 patients
with SCLC, predominantly extensive stage 17 (73.9%). Systemic chemoradiotherapy
was the common first-line treatment for limited-stage SCLC patients, 4 (66.7%),
while extensive-stage patients, 7 (41.2%), received systemic chemoradiotherapy.
The distribution of second-, third and later-lines of treatment was similar
across subtypes. At first-line, the extensive-stage SCLC had a mean treatment
duration of 5.9 ±8.1months, while
limited-stage SCLC had 3.25±1.49months.
About 3(37.5%) of limited-stage patients and 7 (29.2%) of extensive-stage
discontinued first-line treatment due to disease progression. The median
first-line progression-free survival (PFS) was six months for extensive-stage
SCLC. The median overall survival (OS) was 38 months for limited-stage SCLC and
11 months for extensive-stage SCLC. 17 patients with stage-III NSCLC were
included. First-line chemoradiation was administered for 12(70.5%). At first-line,
stage-III NSCLC had a mean treatment duration of 2.29 ±2.98months.
The median first-line PFS was six months, and the median OS was 20 months.
Conclusion: The current data
provide real-world insights into the presentation and management landscape of
both SCLC and stage-III NSCLC in KSA. Further studies with a larger sample size
are recommended.
Keywords
SCLC, small cell lung cancer; NSCLC, non-small cell lung cancer; Stage-III; KSA, Kingdom of Saudi Arabia; limited stage; extensive stage
